# A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

> **NCT06265428** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **DualityBio Inc.** · enrollment: 228 (actual)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** DB-1303/BNT323
- **DRUG:** T-DM1

## Key facts

- **NCT ID:** NCT06265428
- **Lead sponsor:** DualityBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-29
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2025-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06265428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06265428, "A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06265428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*